The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.

This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy.

Inclusion Criteria:

• Patients with chronic HBV；
• Receiving anti-HB viral therapy;
• 10 IU/ml≤HBsAg≤3000 IU/ml.

Exclusion Criteria:

• Patients co-infected with hepatitis C virus, HIV, HAV, HDV, HEV;
• Liver cirrhosis;
• Hepatocellular carcinoma;
• Autoimmune liver disease;
• Clinical hepatic decompensation;
• Fibroscan>12 kPa;
• a. hemoglobin<110g/L（female）<120 g/L（male），platelet<ULN，white blood cell<2.5×109/L；b. bilirubin>1.5 ×ULN，ALT>2 × ULN，serum albumin<35 g/L；c. INR>1.5；d. serum creatinine >1.5×ULN.